Study Shows New Candela Vbeam Perfecta Laser Safely Treats Pigmented and Vascular Lesions Associated with Photoaging.

- New Technology Proves Improved Efficacy, Higher Purpura Threshold, Fewer Side Effects -

WAYLAND, Mass. -- A recent study published in The Journal of Lasers in Surgery and Medicine shows that the new micropulse technology of Candela Corporation's (NASDAQ: CLZR) flagship Vbeam([R]) Pulsed Dye Laser - the Perfecta([TM]), improves efficacy to safely treat vascular and epidermal pigmented lesions while reducing or eliminating undesired side effects such as purpura. The Vbeam Perfecta technology provides patients options when considering skin rejuvenation, fading of sun and age spots, removal of leg and facial veins, treatment of rosacea, dyschromia and more.

"Candela's Vbeam has always been known as the gold standard for treatment of vascular lesions. We were able to improve upon the gold standard with the introduction of epidermal pigmented lesions as well as the advanced micropulse technology that allows our customers to treat cosmetic patients without downtime," said Gerard E. Puorro, Candela's President and Chief Executive Officer. "This pilot study proves that we have been able to achieve highly effective treatments that customers can offer as part of a comprehensive skin care regimen to their patients," Puorro added.

Laser treatment of pigmented lesions is expected to increase 19% in 2007*, making it one of the primary indications for which patients seek laser treatment. The patented pigmented lesion handpiece, developed for Perfecta, adds versatility to pulsed dye technology and allows practitioners to diversify treatment capabilities with a single device.

"This study of Vbeam Perfecta showed that the combination of a modified pulse sequence and pigmented lesion handpiece can effectively and safely treat vascular and pigmented lesions for patients who want fast results and better looking skin without the side effect of bruising that sometimes results with other treatments," said Arielle N.B. Kauvar, M.D., of New York Laser & Skin Care. "Practitioners will now be able to provide their patients with purpura-free laser treatments for skin rejuvenation, pigmented lesions and sun damage, all the symptoms of photoaging."

The Vbeam lasers Aesthtica, Platinum and Perfecta, are part of Candela's new Pathways Purchasing Program, providing upgradeable technologies that provide practitioners with the flexibility to "design" the laser they want depending on the needs of their practice.

(*)Millenium Research Group 2005

About Vbeam: Vbeam features Candela's advanced micro-pulse technology providing consistent and gentle heating, which allows for effective, purpura-free treatment for vascular and epidermal pigmented lesions. Additionally, the digitally enhanced user interface system provides pre-set treatment parameters to allow practitioners to optimize patient treatment results. Vbeam can be used to help correct a wide range of vascular and pigmented lesions including: Rosacea, sun and age spots, face and leg veins, fine lines and wrinkles, port wine stains, hemangiomas, scars, stretch marks, and warts. DCD([R]) is an integrated dynamic cooling device system that automatically emits a cooling spray milliseconds before each pulse to protect the skin and increase patient comfort.

About CANDELA: Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 18 years ago, and currently has an installed base of 10,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer (Male/Female/Handicapped/Veteran). Visit Candela on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, the risk of an adverse judgment in the patent litigation with Palomar Medical Technologies, Inc., (PMTI), dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC, including but not limited to, Candela's Annual Report on Form 10-K for the year ended July 1, 2006. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.